Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-03-25
2004-01-27
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06683102
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to methods for increasing the bioavailability of a medicinal agent, namely metaxalone (5-[(3,5-dimethylphenoxy)methyl]-2 oxazolidinone).
BACKGROUND OF THE INVENTION
Metaxalone (Skelaxin®) has the following chemical structure and name:
5-[(3,5-dimethylphenoxy)methyl]-2 oxazolidinone
Skelaxin is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man. The commecially available tablet contains: metaxalone, 400 mg along with inert compression tableting excipients.
Metaxalone is further described at Monograph no. 5838 of the Merck Index (Eleventh Addition, Merck & Co., 1989) and is also identified by CAS Registry Number: 1665-48-1. It is also known by the drug code, AHR-438; and the drug product containing it is marketed as Skelaxin® (a trademark of Elan Pharmaceuticals, Inc.).
Preparation of metaxalone is described in Lunsford et al., J. Am. Chem. Soc. 82, 1166 (1960) and U.S. Pat. No. 3,062,827 to Lunsford (Nov. 6, 1962 Assignee A. H. Robins), which is incorporated herein in its entirety by reference. The '827 patent discloses the compound and related species as anticonvulsants and antispasmodics, however, these activities have not been borne out by clinical experience.
Metaxalone is a central nervous system depressant that has sedative and skeletal muscle relaxant effects. Metaxalone is indicated as an adjunct to rest, physical therapy and other measures for the relief of discomforts associated with acute, painful muscoloskeletal conditions. See Skelaxin® monograph, 2001 Physicians' Desk Reference®, Medical Economics Company, Inc. (publisher) Montvale, N.J.
The most frequent reactions to metaxalone include nausea, vomiting, gastrointestinal upset, drowsiness, dizziness, headache, and nervousness or “irritability.” Other adverse reactions are: hypersensitivity reaction, characterized by a light rash with or without pruritus; leukopenia; hemolytic anemia; jaundice.
Pharmacokinetic studies have not previously been conducted to date to evaluate the effect of food on the pharmacokinetics of metaxalone. The hydrophobicity of the metaxalone molecule and the dosage amount required for a therapeutic effect both point to probably limited absorption from the gut when administered orally. More oral bioavailability of the drug substance has been sought to increase both speed of onset and amount of therapeutic effect.
REFERENCES:
patent: 3062827 (1962-11-01), Lunsford
patent: 3993767 (1976-11-01), Alphin et al.
patent: 4036957 (1977-07-01), Alphin et al.
patent: 4792449 (1988-12-01), Ausman et al.
patent: 4820690 (1989-04-01), Gregory et al.
patent: 4963361 (1990-10-01), Kawazi
patent: 5538954 (1996-07-01), Koch et al.
patent: 5840688 (1998-11-01), Tso
patent: 5977175 (1999-11-01), Lin
patent: 5989583 (1999-11-01), Amselem
patent: 6017932 (2000-01-01), Singh et al.
patent: 6028054 (2000-02-01), Benet et al.
patent: 6099859 (2000-08-01), Cheng et al.
patent: 6143325 (2000-11-01), Dennis et al.
patent: 6407128 (2002-06-01), Scaife et al.
patent: 2001/0024659 (2001-09-01), Chen et al.
patent: 2002/0009474 (2002-01-01), Adusumilli et al.
Fathie, Kazem, “A second look at a skeletal muscle relaxant: a double-blind study of metaxalone,”Current Therapeutic Research, vol. 6, No. 11, 1964.
Morey et al., “Metaxalone, A New Skeletal Muscle Relaxant,”Journal A.O.A.vol. 62, pp. 517-521 (1963).
Elenbaas, “Centrally Acting Oral Skeletal Muscle Relaxants,”Am. J. Hosp. Pharm. vol. 37, pp. 1313-1323 (1980).
Physicians' Desk Reference, Med. Economics Co. Inc., Oradell NJ, 41stEdition, 1987, p. 827.
“Skeletal Muscle Relaxants (Systemic),” Micromedex, Inc., reported to have been revised Aug. 11, 1995, printed from “http://www.nlm.nih.gov/medilineplus/druginfo/uspdi/202523.html” on Sep. 13, 2002, pp. 1-7.
Kazem Fathie, “Musculoskeletal Disorders and Their Management with a New Relaxant,” printed from “http://www.aanos.org/edctn_msk_disordr.htm” (the website of The American Academy of Neurological and Orthopaedic Surgeons) on Sep. 13, 2002, pp. 1-5.
Kazem Fathie, “Musculoskeletal Disorders and Their Management with a New Relaxant,”Clinical Medicine, Apr. 1965, pp. 678-682.
Lunsford et al., 5-Aryloxymethyl-2-oxazolidinones, J. of Am. Chemical Soc., vol. 82, No. 5, Mar. 1960, pp. 1166-1171.
Physicians' Desk Reference, Med. Economics Co. Inc, Montvale NJ, 55thEdition, 2001, p. 1080.
The Merck Index, 11thedition, (Budavari et al Eds.) Merck & Co., Inc., Rahway NJ, 1989, pp. 933-934.
Complaint for Patent Infringement dated Jan. 2, 2003 and filed on behalf of plaintiff Elan Pharmaceuticals, Inc. inElan Pharmaceuticals, Inc. v. Eon Labs, Inc.CV 03 0006 (RDJ, RLM).
Complaint for Patent Infringement dated Mar. 7, 2003 and filed on behalf of plaintiff Elan Pharmaceuticals, Inc. inElan Pharmaceuticals, Inc. v. Corepharma, LLCCV 031013 (DMC).
U.S. patent application Ser. No. 10/386,113, filed on Mar. 2003, Scaife et al.
U.S. patent application Ser. No. 10/420,804, filed on Apr. 2003, Scaife et al.
Scaife Michael
Shah Jaymin
Elan Pharmaceuticals Inc.
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Henley III Raymond
LandOfFree
Methods of using metaxalone in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using metaxalone in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using metaxalone in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3246836